The primary objectives of this study were to assess the efficacy and safety of Lys( @entity18752 ), Pro(B29) in the treatment of @entity1 with @entity6 and to compare Lys( @entity18752 ), Pro(B29) to currently available regular @entity2690 with respect to quality of life. This study was designed as an open-label, non-comparative one. The number of @entity1 enrolled in the trial was 39. At Visit 1 (week 0), blood samples for fasting, 1- and 2-hour postprandial blood @entity413 , and HbA1c were taken. At Visit 2 (week 6) and Visit 3 (week 12), fasting, 1- and 2-hour postprandial blood @entity413 , and HbA1c levels were measured again. There was no significant change in HbA1c, fasting blood @entity413 and 1- and 2-hour postprandial blood @entity413 levels. The 1- and 2-hour postprandial blood @entity413 excursions decreased significantly from Visit 1 to Visit 3. There were no serious adverse events during the study. Half of the @entity1 had less @entity4053 with LysPro @entity2690 , while 25% had an increase in episodes. Thirty percent of @entity1 were more satisfied with LysPro @entity2690 than with the short-acting @entity2690 that they had previously used. In conclusion, LysPro therapy can be regarded as safe, since there were no unexpected adverse events and no changes in the usual physical parameters.

Safety and efficacy of [Lys( @entity18752 ), Pro(B29)]- @entity1 @entity2690 in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity18752 :: ('54069', 'Gene') :: ['B28'] @entity2690 :: ('3630', 'Gene') :: ['insulin'] @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity6 :: (MESH:D003920,Disease) :: ['diabetes mellitus']
